Research
Evidence, read off the primary source — page 5
No pattern-matched citations and no PMIDs pulled from memory. Every regulatory date, study, and label quote below was checked against its primary source before publication — see each article's reference list. 134 articles published so far.
How we verify a source
A PubMed citation is checked against PubMed's own record, not typed from recall. A regulatory page is read at the source and quoted, not paraphrased from a secondary blog. If a claim cannot be verified this way, it is softened or removed — never guessed.
Filter by topic
Showing 97–120 of 134 articles
Evidence review
Survodutide: What the Evidence Actually Shows
Survodutide has real, published Phase 3 obesity and liver-disease trial data — and no approval anywhere. Here's the current status, live-verified.
ReadEvidence review
TB-500 Dosage and Side Effects: What Studies Actually Used — Not a Recommendation
TB-500 has no FDA-approved dose and almost no safety data of its own. Here's the single animal dose figure that exists, and what's actually known — not advice.
ReadEvidence review
Tesofensine: What the Evidence Actually Shows
Tesofensine's weight loss was a Parkinson's-drug side effect. Its general-obesity program was never finished — here's what actually happened, live-verified.
ReadEvidence review
Thymalin: What the Evidence Actually Shows
Thymalin is a Soviet-era thymus extract, chemically distinct from Thymosin Alpha-1 and Beta-4 despite the name. Here's its own real evidence base.
ReadEvidence review
Thymosin Alpha-1: What the Evidence Actually Shows
Thymosin Alpha-1 is approved in 35+ countries as Zadaxin — but never in the U.S. Here's the real approval split, and what the human trials actually found.
ReadEvidence review
Thymosin Beta-4: What the Evidence Actually Shows
Full-length thymosin beta-4 has two real, separate human drug programs — one topical, one an active Chinese IV trial. Neither is what's sold as TB-500.
ReadEvidence review
Tirzepatide vs. Semaglutide: What the Head-to-Head Trials Actually Show
A real randomized head-to-head trial compared tirzepatide and semaglutide directly. What it found, and what it doesn't tell you about a compounded vial.
ReadEvidence review
VIP (Vasoactive Intestinal Peptide): What the Evidence Actually Shows
VIP is a real human neuropeptide under active FDA review — but its best-known use, the Shoemaker CIRS protocol, has no independent efficacy trial behind it.
ReadEvidence review
VK2735: What the Evidence Actually Shows
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP agonist, now in Phase 3. Real trial data for both its injectable and oral tablet forms.
ReadEvidence review
What Is Compounded Semaglutide? How It Differs From Wegovy and Ozempic, and the One Problem That Is Unique to It
Compounded semaglutide is not FDA-approved and not a generic. Here is how it differs from Wegovy and Ozempic — including a salt-form problem unique to it.
ReadEvidence review
Wolverine Stack: What the Evidence Shows
The Wolverine stack pairs BPC-157 and TB-500. A real rat study tested that exact combination — and found no added benefit from stacking them.
ReadEvidence review
BPC-157 Before and After: What Is Actually Documented vs. Anecdotal — and How Long It Takes
"Before and after" content for BPC-157 is mostly anecdote. Here's the real, controlled healing-timeline data from animal studies, and how long it takes to work.
ReadEvidence review
BPC-157 Side Effects: What the Animal Studies, Human Pilot Data, and Regulatory Record Actually Show
BPC-157 has no FDA label or adverse-reaction table. Here's what animal safety data, three tiny human pilots, and the regulatory record actually report.
ReadEvidence review
BPC-157: What the Evidence Actually Shows
BPC-157 is marketed almost entirely on animal studies. Here's what the rodent research actually found, what human evidence exists, and what's missing.
ReadEvidence review
Does GLP-1 Therapy Affect Your Period? What the Evidence Actually Shows
Does semaglutide or tirzepatide change your period? A 2026 pharmacovigilance study found real signals — here's what it found, and the older explanation too.
ReadEvidence review
DSIP: What the Evidence Actually Shows
DSIP is sold for sleep and stress. Here's what 1970s-90s human trials actually found, and why its own identity as a hormone is scientifically disputed.
ReadEvidence review
Epitalon: What the Evidence Actually Shows
Epitalon is sold for telomere length and longevity. Here's what a live PubMed search actually found — and why most of it traces to one lab.
ReadEvidence review
GHK-Cu: What the Evidence Actually Shows
GHK-Cu has real human trials behind its topical form — and almost none behind the injectable one. Here's what separates the two evidence records.
ReadEvidence review
GLP-1 Weight Loss, Loose Skin, and Body Changes: What the Evidence Actually Shows
Rapid GLP-1 weight loss can leave loose skin. Here's the real mechanism, what resistance training and GHK-Cu evidence actually shows, and what doesn't help.
ReadEvidence review
Is Compounded Semaglutide Still Legal? What the FDA Actually Says
FDA declared the semaglutide shortage resolved in February 2025 — a different timeline and court docket than tirzepatide's. Here is the agency's own record.
ReadEvidence review
Is Compounded Tirzepatide Still Legal? What the FDA Actually Says
The FDA declared the tirzepatide shortage resolved in 2024. Here is what that actually changed for compounding pharmacies, read off the agency's own timeline.
ReadEvidence review
Is Sermorelin Safe? A Direct Verdict on What the Evidence Actually Shows
Is sermorelin safe? Here's a direct verdict: what its trials found, what its post-marketing record shows, and the real gaps in the evidence that remain.
ReadEvidence review
KPV: What the Evidence Actually Shows
KPV is sold as a gentler, gut-healing peptide. Here's what the rodent colitis research actually found, and why zero human trials have been published.
ReadEvidence review
Melanotan II: What the Evidence Actually Shows
Melanotan II is sold for tanning and libido. Here's what its own trial data and a growing case-report record of melanoma and cardiovascular harm actually show.
Read
Nothing matches these filters
No article matches both the search text and the topic selected. Try clearing one of the two filters.